(0.89%) 5 063.06 points
(0.85%) 38 224 points
(1.45%) 15 832 points
(0.13%) $79.10
(5.69%) $2.04
(0.25%) $2 316.70
(0.56%) $26.90
(1.12%) $965.55
(-0.06%) $0.932
(-0.36%) $10.99
(-0.04%) $0.798
(-1.36%) $91.99
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 14.92%
@ $9.20
Išleistas: 15 kov. 2024 @ 21:39
Grąža: -30.71%
Ankstesnis signalas: kov. 15 - 15:44
Ankstesnis signalas:
Grąža: 0.77 %
Live Chart Being Loaded With Signals
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases...
Stats | |
---|---|
Šios dienos apimtis | 408 689 |
Vidutinė apimtis | 2.31M |
Rinkos kapitalizacija | 438.64M |
EPS | $0 ( 2024-02-22 ) |
Kita pelno data | ( $-0.350 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.39 |
ATR14 | $0.00900 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-14 | Mossler Mark | Buy | 27 430 | Stock Option (Right to Buy) |
2024-02-14 | Mossler Mark | Buy | 18 290 | Common Stock |
2024-04-01 | Anderson Kenneth Carl | Buy | 1 389 | Common Stock |
2024-04-01 | Dubin Glenn | Buy | 1 358 | Common Stock |
2024-04-01 | Grogan Donna Roy | Buy | 1 697 | Common Stock |
INSIDER POWER |
---|
59.68 |
Last 98 transactions |
Buy: 4 435 645 | Sell: 1 001 966 |
Tūris Koreliacija
C4 Therapeutics, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
QRTEA | 0.96 |
PTRA | 0.959 |
EIGR | 0.957 |
STIM | 0.957 |
ASPU | 0.955 |
SSP | 0.955 |
MDRX | 0.954 |
AKTX | 0.954 |
PRCH | 0.954 |
PSTX | 0.952 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
STAY | -0.951 |
CCRC | -0.95 |
SGEN | -0.947 |
PAE | -0.944 |
EBSB | -0.94 |
PTOC | -0.931 |
DSPG | -0.93 |
PPYAU | -0.929 |
RAM | -0.92 |
LMNR | -0.918 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
C4 Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos
C4 Therapeutics, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $20.76M |
Bruto pelnas: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2023 |
Pajamos: | $20.76M |
Bruto pelnas: | $13.02M (62.72 %) |
EPS: | $-2.67 |
FY | 2022 |
Pajamos: | $31.10M |
Bruto pelnas: | $23.52M (75.65 %) |
EPS: | $-2.59 |
FY | 2021 |
Pajamos: | $45.79M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1.730 |
Financial Reports:
No articles found.
C4 Therapeutics, Inc.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.